Latest Content

Long-term adherence to healthy behaviors reduces the risk of cardiovascular disease and type 2 diabetes, even among individuals taking antihypertensive medications.

The complete response letter marks the second time that reproxalap, a medication for use in dry eye disease, has been rejected by the FDA.

Study links PFAS and forever chemicals in children and teens to lower bone density in adolescents—especially girls—highlighting critical exposure windows.

Researchers find that epigenetic changes from the famine caused CV and mental health effects for 3 to 4 generations on both sides of the Atlantic.

Rising global temperatures are silently driving a sedentary crisis, and the world’s most vulnerable populations are paying the steepest price.

Severe COVID-19 was rare in patients with multiple sclerosis even when vaccine responses were impaired.

Secukinumab becomes the only IL-17A inhibitor approved for this population and the first new mechanism in the indication in nearly a decade.